A 2-treatment Period, Randomized, Placebo-controlled, Multicenter Parallel-group Study to Assess the Safety of QAW039 When Added to Existing Asthma Therapy in GINA Steps 3, 4 and 5 Patients With Uncontrolled Asthma.

Trial Profile

A 2-treatment Period, Randomized, Placebo-controlled, Multicenter Parallel-group Study to Assess the Safety of QAW039 When Added to Existing Asthma Therapy in GINA Steps 3, 4 and 5 Patients With Uncontrolled Asthma.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Aug 2018

At a glance

  • Drugs Fevipiprant (Primary)
  • Indications Asthma
  • Focus Adverse reactions; Registrational
  • Acronyms SPIRIT
  • Sponsors Novartis
  • Most Recent Events

    • 27 Jun 2018 Planned number of patients changed from 2314 to 1570.
    • 27 Jun 2018 Planned End Date changed from 15 Jul 2022 to 18 Nov 2022.
    • 27 Jun 2018 Planned primary completion date changed from 15 Jul 2022 to 18 Nov 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top